Related Experiment Videos
Clenbuterol-induced tardive dyskinesia
1Hospital de Clinicas José de San Martin, Neurology Department, University of Buenos Aires, Argentina.
Clinical Neuropharmacology
|October 1, 1991
Summary
Long-term use of clenbuterol, a medication for obstructive lung disease, can cause persistent dyskinetic movements, particularly affecting respiratory muscles. Reserpine effectively treated these movements, highlighting a potential adverse effect of clenbuterol therapy.
Area of Science:
- Pharmacology
- Neurology
- Respiratory Medicine
Background:
- Clenbuterol is a beta-2 agonist bronchodilator used for obstructive lung disease.
- Long-term medication effects can present with varied and sometimes unexpected adverse events.
Observation:
- A 73-year-old male patient with obstructive lung disease developed dyskinetic movements after 5 years of clenbuterol (20 mg twice daily).
- The movements primarily involved respiratory muscles and mimicked neuroleptic-induced dyskinesias.
- These abnormal movements persisted even after discontinuing clenbuterol.
Findings:
- Clenbuterol-induced dyskinesia is a potential long-term adverse effect.
- Reserpine demonstrated efficacy in managing clenbuterol-induced dyskinetic movements.
Implications:
- Clinicians must consider clenbuterol as a potential cause of dyskinetic movements in patients with obstructive lung disease.
- Awareness of this adverse effect is crucial for patient safety during long-term clenbuterol treatment.
- Further research into the neurotoxic mechanisms of clenbuterol may be warranted.